Advertisement
HROW vs RDY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HROW is a StrongBuy and RDY is a StrongBuy.
HROW's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for HROW turned positive on October 20, 2026. Looking at past instances where HROW's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HROW's RSI Oscillator exited the oversold zone, 32 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on HROW as a result. In 67 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
Following a +1.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where HROW advanced for three days, in 239 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
HROW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HROW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for HROW entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. HROW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HROW's P/B Ratio (72.485) is slightly higher than the industry average of (8.801). P/E Ratio (-29.687) is within average values for comparable stocks, (-2.500). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
RDY's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for RDY turned positive on October 09, 2026. Looking at past instances where RDY's MACD turned positive, the stock continued to rise in 30 of 47 cases over the following month. The odds of a continued upward trend are 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RDY as a result. In 42 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 50%.
The 10-day moving average for RDY crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.
Following a +1.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where RDY advanced for three days, in 154 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
The Aroon Indicator entered an Uptrend today. In 89 of 243 cases where RDY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 37%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RDY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
RDY broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. RDY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.031) is normal, around the industry mean (8.801). P/E Ratio (0.356) is within average values for comparable stocks, (-2.500). Projected Growth (PEG Ratio) (1.666) is also within normal values, averaging (2.152). Dividend Yield (0.021) settles around the average of (0.044) among similar stocks. P/S Ratio (2.817) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RDY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron SMR rating for this company is 73 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
HROW | RDY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 63 | 69 | |
SMR RATING 1..100 | 99 | 73 | |
PRICE GROWTH RATING 1..100 | 78 | 43 | |
P/E GROWTH RATING 1..100 | 14 | 97 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RDY's Valuation (49) in the Pharmaceuticals Generic industry is somewhat better than the same rating for HROW (87) in the Pharmaceuticals Other industry. This means that RDY’s stock grew somewhat faster than HROW’s over the last 12 months.
HROW's Profit vs Risk Rating (63) in the Pharmaceuticals Other industry is in the same range as RDY (69) in the Pharmaceuticals Generic industry. This means that HROW’s stock grew similarly to RDY’s over the last 12 months.
RDY's SMR Rating (73) in the Pharmaceuticals Generic industry is in the same range as HROW (99) in the Pharmaceuticals Other industry. This means that RDY’s stock grew similarly to HROW’s over the last 12 months.
RDY's Price Growth Rating (43) in the Pharmaceuticals Generic industry is somewhat better than the same rating for HROW (78) in the Pharmaceuticals Other industry. This means that RDY’s stock grew somewhat faster than HROW’s over the last 12 months.
HROW's P/E Growth Rating (14) in the Pharmaceuticals Other industry is significantly better than the same rating for RDY (97) in the Pharmaceuticals Generic industry. This means that HROW’s stock grew significantly faster than RDY’s over the last 12 months.
| HROW | RDY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 78% | 1 day ago 58% |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 53% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 50% |
| MACD ODDS (%) | 1 day ago 83% | 1 day ago 64% |
| TrendWeek ODDS (%) | 1 day ago 79% | 1 day ago 49% |
| TrendMonth ODDS (%) | 1 day ago 83% | 1 day ago 45% |
| Advances ODDS (%) | 1 day ago 82% | 10 days ago 49% |
| Declines ODDS (%) | 16 days ago 79% | 16 days ago 55% |
| BollingerBands ODDS (%) | 1 day ago 75% | 1 day ago 65% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 37% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HROW’s FA Score shows that 1 FA rating(s) are green while RDY’s FA Score has 0 green FA rating(s).
- HROW’s FA Score: 1 green, 4 red.
- RDY’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HROW’s TA Score shows that 5 TA indicator(s) are bullish while RDY’s TA Score has 5 bullish TA indicator(s).
- HROW’s TA Score: 5 bullish, 3 bearish.
- RDY’s TA Score: 5 bullish, 4 bearish.
Price Growth
HROW (@Pharmaceuticals: Generic) experienced а +4.07% price change this week, while RDY (@Pharmaceuticals: Generic) price change was +7.28% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.99%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was +6.10%.
Reported Earning Dates
HROW is expected to report earnings on Nov 09, 2026.
RDY is expected to report earnings on Jan 22, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.99% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement